Low-affinity antibodies are more likely to bind selectively to cells with extremely high EpCAM expression and penetrate deeper by avoiding ‘binding barrier’ to distribute less heterogeneously in the tumour tissue, reducing off-target effects [38]. This evidence concerns the gene EPCAM and neoplasm.